“…Despite significant improvements, clinical responses to DC vaccines remain largely frail due to hurdles related to insufficient antigen cross-presentation, impaired migratory capacity, and/or weak cytokine release. 42 , 43 , 44 , 45 , 46 , 47 , 48 With these limitations in perspective, we engineered IRMs, a type of non-hematopoietic APCs capable of surpassing DCs at mounting potent anti-tumoral responses against both murine T-cell lymphoma and melanoma caused by EG.7 and B16 cells, respectively. 11 Although exhibiting impressive potencies in pre-clinical models, the IRM vaccination protocol used so far is logistically impractical.…”